Moderna Biotechnology (MRNA) is a clinical stage biotechnology company that develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.
Everyone is talking about brand new stocks in the biotechnology industry. Moderna Biotech is a new stock that had the IPO last December 2018, it’s only one year and a few months old. Supply and demand is the force that governs the financial markets and our daily lives. Moderna Biotech (MRNA) is not an exception.
Moderna Biotech could be one of the companies that develops a cure and vaccine for the new coronavirus. The outlook for health-care companies has become murkier as fears over the novel coronavirus epidemic loom over the market. If the local epidemics in China and other countries spread and become a pandemic in the coming weeks, health-care companies will be on the front line and could become good assets to own long term.
Let’s have a look at the weekly timeframe. As you can see below we have a strong bullish impulse created around 19-20$ per share. That’s where we are interested in buying this biotechnology stock if it ever retraces down there and the stock is still in a clear uptrend.
The big story in biotechnology this past week has been the rise and fall of the share prices Gilead Sciences and the stock we are analysing in this post, Moderna (MRNA). These two companies have drawn a lot of attention for their progress on a treatment and a vaccine for the coronavirus.
We can see how supply and demand technical analysis on Moderna Biotechnology is telling us there is a huge imbalance in the weekly timeframe. That’s all we need to know, a huge imbalance where to buy the underlying biotech stock if it ever retraces down there.
The new drugs seem promising, the supply and demand stock analysis is showing exactly that. This is the kind of stock technical analysis we should be performing on every single stock.
Disclaimer: Any Advice or information on this website is General Advice Only - It does not take into account your personal circumstances, please do not trade or invest based solely on this information. By viewing any material or using the information within this site you agree that this is general education material and you will not hold any person or entity responsible for loss or damages resulting from the content or general advice provided here by Set and Forget, its employees, or fellow members. Futures, options, and spot currency and stocks trading have large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the Forex and futures markets. Don't trade with money you can't afford to lose. This website is neither a solicitation nor an offer to Buy/Sell spot Forex, cfd's, stocks or other financial products. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed in any material on this website. The past performance of any trading system or methodology is not necessarily indicative of future results.
High Risk Warning: Forex, Futures, and Options trading has large potential rewards, but also large potential risks. The high degree of leverage can work against you as well as for you. You must be aware of the risks of investing in Forex, futures, and options and be willing to accept them in order to trade in these markets. Forex trading involves substantial risk of loss and is not suitable for all investors. Please do not trade with borrowed money or money you cannot afford to lose. Any opinions, news, research, analysis, prices, or other information contained on this website is provided as general market commentary and does not constitute investment advice. We will not accept liability for any loss or damage, including without limitation to, any loss of profit, which may arise directly or indirectly from the use of or reliance on such information. Please remember that the past performance of any trading system or methodology is not necessarily indicative of future results.